Our new @vkprasadlab article is now out in Cancer Reports
We tackle the frequency (spoiler alert: BRISK) of assessment of progression in RCTs of cancer drugs
Want to learn more?
onlinelibrary.wiley.com/doi/epdf/10.10…
[thread]
First, remember that progression free survival is a time to event, composite endpoint
It is typically the time until 1 of 4 things happen
Death, New lesions, Growth (without shrinkage) or Growth (from Nadir).
Watch my free lecture series to learn more:
As a result PFS is binned
It has a stair-step pattern b/c imaging is assessed not continuously, but at pre-specified time points
One can imagine that as a result: how often you assess the endpoint is important.
Very frequent assessment is rare in the messy reality of life, but might be common in trials
This can turn even trivial changes in tumor growth in stat. significant p values of <0.05!
aka $
We assessed how often PFS was checked in trials in our paper
Indeed it is checked frequently. Often less than 8 weeks is mandated for protocol specified scans.
Relentless scanning may be a tactic to find significant results for small gains
In many cases, the frequency of scanning in trials is more than guideline recommendations
Our study could not find a difference in the hazard ratio comparing different trials with different scan intervals, but this caveat is important to consider 👇👇
A future study should compare real world scan intervals to trial scan intervals. If anyone has access to data & is interested; email our lab, we would love to collaborate
@vkprasadlab
Read the full paper here:
onlinelibrary.wiley.com/doi/epdf/10.10…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.